Cell Replacement Therapies For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Cell replacement therapies aim to restore lost neuronal populations and support neural circuitry in neurodegenerative diseases. These approaches involve transplantation of various cell types to replace degenerating neurons, provide neurotrophic support, or modulate immune responses.
- Dopaminergic neurons: For Parkinson's disease
- Motor neurons: For ALS
- Cholinergic neurons: For Alzheimer's disease
- GABAergic neurons: For Huntington's disease
- Patient-derived cells reduce immune rejection risk
- Autologous transplantation potential
- Disease-specific modeling possible
- Immunomodulatory properties
- Secretion of neurotrophic factors
- Easy isolation from bone marrow or adipose tissue
- Capacity to differentiate into multiple neural lineages
- Support endogenous repair mechanisms
- Potential for integration into host circuitry
- Support olfactory neuron regeneration
- Bridging capabilities for spinal cord injury
- Investigational for PD and ALS
- Cell source: Fetal ventral mesencephalon, embryonic stem cells, iPSCs
**: Stri- **Target regionatum (caudate and putamen)
- Mechanism: Replace degenerated dopaminergic neurons
- Clinical outcomes:
- Improved motor function in selected patients
- Reduced levodopa requirements
- Long-term survival of grafted cells demonstrated
- Challenges:
- Need for immunosuppression
- Variable graft outcomes
- Risk of dyskinesias
- Cell source: Fetal striatal tissue, ESC-derived medium spiny neurons
- Target region: Striatum
- Clinical trials: Ongoing with mixed results
- Approaches:
- Intrastriatal transplantation
- Multiple injection tracks for coverage
- Cell sources: Neural stem cells, embryonic stem cells
- Delivery: Intraspinal or intracerebral
- Mechanisms:
- Direct cell replacement
- Neurotrophic factor secretion
- Immunomodulation
- Target: Basal forebrain cholinergic system
- Cell sources: Neural stem cells, genetically modified cells
- Goals: Restore cholinergic innervation to hippocampus and cortex
- Precise targeting of specific brain regions
- Multiple injection tracks for broad coverage
- Used for Parkinson's and Huntington's disease
- Cells delivered into ventricular system
- Allows distribution via CSF
- Used for diffuse CNS diseases
- For motor neuron diseases
- Cervical and lumbar regions targeted
- Technical challenges due to spinal cord sensitivity
- Less invasive than direct CNS injection
- Requires cells that can cross blood-brain barrier
- Currently experimental
| Phase |
Disease |
Cell Type |
Status |
| I/II |
Parkinson's |
Fetal dopaminergic neurons |
Completed |
| I |
Parkinson's |
iPSC-derived dopaminergic neurons |
Recruiting |
| I |
ALS |
Neural stem cells |
Completed |
| I |
Huntington's |
Striatal progenitors |
Completed |
| I |
Alzheimer's |
Mesenchymal stem cells |
Recruiting |
¶ Challenges and Limitations
- Need for immunosuppression with allogeneic cells
- iPSC-derived autologous cells reduce rejection risk
- Axonal outgrowth to appropriate targets
- Synaptic formation with host neurons
- Electrical integration into neural circuits
- Undifferentiated cell contamination
- Need for rigorous quality control
- Tumor formation observed in some preclinical models
- Fetal tissue use
- Embryonic stem cell derivation
- Clinical trial design with informed consent
- Engineering cells for enhanced survival
- Expressing neurotrophic factors
- Resistance to toxic protein aggregation
- Providing structural support for transplanted cells
- Controlled release of supportive factors
- Biodegradable materials for safety
- Combining cell therapy with anti-inflammatory treatments
- Enhancing graft survival
- Modulating disease progression
- Autologous transplantation
- Disease-specific cell lines
- Gene-corrected patient cells
- Precise cell placement
- Complex tissue constructs
- Vascularization strategies
- Brain organoid transplantation
- Circuit-level reconstruction
- Advanced disease modeling
The study of Cell Replacement Therapies For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:28632460 - Clinical transplantation of dopaminergic neurons for Parkinson's disease
- PMID:28854705 - iPSC-derived neurons for Parkinson's disease therapy
- PMID:28983656 - Neural stem cell therapy for ALS
- PMID:29084523 - Cell replacement therapy for Huntington's disease
- PMID:29167912 - Mesenchymal stem cells in neurodegenerative disease treatment
- PMID:29254987 - Challenges in cell therapy for CNS disorders
- PMID:29354723 - Next-generation stem cell therapies for Parkinson's disease
- PMID:29452894 - Clinical trials of cell therapy: regulatory considerations